Novaccess Global Inc (XSNX)
0.015
+0.01
(+80.72%)
USD |
OTCM |
May 17, 16:00
Novaccess Global Enterprise Value: 2.601M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 2.601M |
| May 16, 2024 | 2.416M |
| May 15, 2024 | 2.332M |
| May 14, 2024 | 2.352M |
| May 13, 2024 | 2.366M |
| May 10, 2024 | 2.380M |
| May 09, 2024 | 2.352M |
| May 08, 2024 | 2.338M |
| May 07, 2024 | 2.360M |
| May 06, 2024 | 2.366M |
| May 03, 2024 | 2.366M |
| May 02, 2024 | 2.366M |
| May 01, 2024 | 2.379M |
| April 30, 2024 | 2.380M |
| April 29, 2024 | 2.338M |
| April 26, 2024 | 2.327M |
| April 25, 2024 | 2.327M |
| April 24, 2024 | 2.380M |
| April 23, 2024 | 2.407M |
| April 22, 2024 | 2.380M |
| April 19, 2024 | 2.399M |
| April 18, 2024 | 2.407M |
| April 17, 2024 | 2.436M |
| April 16, 2024 | 2.41M |
| April 15, 2024 | 2.463M |
| Date | Value |
|---|---|
| April 12, 2024 | 2.470M |
| April 11, 2024 | 2.490M |
| April 10, 2024 | 2.490M |
| April 09, 2024 | 2.532M |
| April 08, 2024 | 2.559M |
| April 05, 2024 | 2.468M |
| April 04, 2024 | 2.490M |
| April 03, 2024 | 2.532M |
| April 02, 2024 | 2.507M |
| April 01, 2024 | 2.507M |
| March 28, 2024 | 2.463M |
| March 27, 2024 | 2.410M |
| March 26, 2024 | 2.504M |
| March 25, 2024 | 2.504M |
| March 22, 2024 | 2.504M |
| March 21, 2024 | 2.490M |
| March 20, 2024 | 2.465M |
| March 19, 2024 | 2.504M |
| March 18, 2024 | 2.518M |
| March 15, 2024 | 2.559M |
| March 14, 2024 | 2.573M |
| March 13, 2024 | 2.586M |
| March 12, 2024 | 2.559M |
| March 11, 2024 | 2.559M |
| March 08, 2024 | 2.559M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
0.4239M
Minimum
Apr 27 2020
11.55M
Maximum
Jul 14 2021
3.900M
Average
3.981M
Median
Jun 23 2023
Enterprise Value Benchmarks
| CEL-SCI Corp | 63.47M |
| AIM ImmunoTech Inc | 7.729M |
| IGC Pharma Inc | 34.45M |
| NovaBay Pharmaceuticals Inc | 5.156M |
| Protalix BioTherapeutics Inc | 55.51M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.304M |
| Total Expenses (Quarterly) | 0.2575M |
| EPS Diluted (Quarterly) | 0.01 |
| Earnings Yield | -666.7% |
| Operating Earnings Yield | 8.88% |
| Normalized Earnings Yield | 38053.43 |